相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation
Paula Granado-Martinez et al.
COMMUNICATIONS BIOLOGY (2020)
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1
Theresa A. Proia et al.
CLINICAL CANCER RESEARCH (2020)
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Ferdinandos Skoulidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Sonja Althammer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Scott J. Antonia et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Prediction of Deleterious Non-synonymous SNPs of Human STK11 Gene by Combining Algorithms, Molecular Docking, and Molecular Dynamics Simulation
Md. Jahirul Islam et al.
SCIENTIFIC REPORTS (2019)
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Shunsuke Kitapma et al.
CANCER DISCOVERY (2019)
Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers
Carminia Maria Della Corte et al.
CANCER DISCOVERY (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma
Jerome Biton et al.
CLINICAL CANCER RESEARCH (2018)
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
Brandon W. Higgs et al.
CLINICAL CANCER RESEARCH (2018)
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
Yu-Lin Su et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype
Juliana B. Candido et al.
CELL REPORTS (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.
Maria Jure-Kunkel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
[Anonymous]
NATURE REVIEWS DRUG DISCOVERY (2018)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients
Liangliang Wu et al.
ONCOTARGET (2017)
Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation
Jingjiao Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto et al.
DIAGNOSTIC PATHOLOGY (2016)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study
Scott Antonia et al.
LANCET ONCOLOGY (2016)
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
Liyan Jiang et al.
PLOS GENETICS (2016)
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Sylvie M. Guichard et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist
David J. Nicholls et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM
Hikmat Assi et al.
PLOS ONE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Dendritic Cell (DC)-Specific Targeting Reveals Stat3 as a Negative Regulator of DC Function
Jessica A. Meliilo et al.
JOURNAL OF IMMUNOLOGY (2010)
Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells
Melissa G. Lechner et al.
JOURNAL OF IMMUNOLOGY (2010)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome
M. Sanchez-Cespedes
ONCOGENE (2007)
Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation
Uddalak Bharadwaj et al.
CANCER RESEARCH (2007)
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu et al.
NATURE REVIEWS IMMUNOLOGY (2007)
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1
JM Lizcano et al.
EMBO JOURNAL (2004)
Regulatory activity of autocrine IL-10 on dendritic cell functions
S Corinti et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
